详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Polymorphs, co-crystal structure and pharmacodynamics study of MBRI-001, a deuterium-substituted plinabulin derivative as a tubulin polymerization inhibitor.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [a]School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China [b]Innovation Center for Marine Drug Screening and Evaluation, Qingdao National Laboratory for Marine Science and Technology, Qingdao 266071, China [c]Marine Biomedical Research Institute of Qingdao, Qingdao 266071, China [d]Precision Medicine Research Center, Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China [e]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University and Collaborative Innovation Center of Biotherapy and Cancer, Chengdu 610041, China

出处：

DOI：

ISSN：

关键词： MBRI-001 Polymorphs Co-crystal structure Tubulin inhibition Anti-cancer agent

摘要：

MBRI-001, a deuterium-substituted plinabulin derivative, has been reported to have better pharmacokinetic and similar antitumor effects in comparison with plinabulin. In this approach, we further carried out its polymorphs, co-crystal structure of MBRI-001-tubulin and tubulin inhibition study. Among the different polymorphs, Form F (MBRI-001/H2O) was prepared and evaluated, which had better physical stability and suitable process for scale-up production. Co-crystal structure of MBRI-001-tubulin (PDB:5XI5) was prepared and analyzed. The result of tubulin polymerization assay demonstrated that MBRI-001 could inhibit tubulin polymerization which was similar as plinabulin. Subsequently, the anti-proliferative activities of plinabulin and MBRI-001 were evaluated against two different human lung cancer cell lines. In vivo study, MBRI-001 revealed similar antitumor inhibition in comparison with plinabulin in A549 xenograft tumor model. Therefore, we suggested that MBRI-001 could be developed as a promising anti-cancer agent in near future. Copyright © 2019 Elsevier Ltd. All rights reserved.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2019]版：

大类 | 3 区医学

小类 | 2 区有机化学 3 区生化与分子生物学 3 区药物化学

最新[2023]版：

大类 | 3 区医学

小类 | 2 区有机化学 3 区生化与分子生物学 3 区药物化学

第一作者：

第一作者机构： [a]School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China

共同第一作者：

通讯作者：

通讯机构： [a]School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China [b]Innovation Center for Marine Drug Screening and Evaluation, Qingdao National Laboratory for Marine Science and Technology, Qingdao 266071, China [c]Marine Biomedical Research Institute of Qingdao, Qingdao 266071, China [e]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University and Collaborative Innovation Center of Biotherapy and Cancer, Chengdu 610041, China [*1]School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]A Rationale for Drug Design Provided by Co-Crystal Structure of IC261 in Complex with Tubulin [2]Development of novel phenoxy-diketopiperazine-type plinabulin derivatives as potent antimicrotubule agents based on the co-crystal structure. [3]Design, synthesis, and antitumor evaluation of quinazoline-4-tetrahydroquinoline chemotypes as novel tubulin polymerization inhibitors targeting the colchicine site [4]Chemical and Biological Evidence of the Efficacy of Shengxian Decoction for Treating Human Lung Adenocarcinoma. [5]Durvalumab Plus Anlotinib Versus Durvalumab as Maintenance Treatment in ES-SCLC (DURABLE): A Randomized, Phase 2 Trial [6]医院后勤精细化管理策略研究 [7]个性化目标教学在神经外科护理实习生带教中的应用 [8]纳米增强免疫比浊法和高效液相色谱法检测化疗患者5-氟尿嘧啶血药浓度的比较 [9]徒手淋巴引流对乳腺癌术后淋巴水肿的治疗效果分析 [10]护理干预在减轻妇科恶性肿瘤腹部术后疼痛中的效果